Gastrointestinal (GI) disorders include a wide range of conditions affecting the GI tract. The GI tract comprises a system of organs that are organised sequentially to form a hollow tube that facilitates the passage of food through the body.
In patients with gastrointestinal disorders, damage to or dysfunction of these organs can elicit some unpleasant symptoms which vary depending upon the organ affected and disease severity. Common symptoms indicative of gastrointestinal involvement include abdominal pain, bloating, nausea, vomiting and abnormal bowel movements.
Though the underlying causes of these gastrointestinal disorders may vary, bacterial infection commonly precipitates onset of symptoms in these patients. For instance, gastritis and duodenitis, which involve inflammation of the stomach lining and duodenum respectively, are frequently associated with infection by Helicobacter pylori. An ulcer that occurs on the duodenum is termed a duodenal or peptic ulcer.
Similarly, the introduction of pathogenic microorganisms into the normally sterile environment of the peritoneum can cause peritonitis, which involves inflammation of the membrane that lines the abdominal cavity.
Certain drugs may also induce gastrointestinal disorders and in other cases, gastrointestinal symptoms may be attributed to genetic disorders, including rare conditions such as acute hepatic porphyria.
Treatment for gastrointestinal disorders varies significantly depending on the underlying cause and severity of symptoms.
To discover more about one of the lesser known causes of gastrointestinal symptoms, visit our dedicated Acute Hepatic Porphyria Learning Zone which includes information on the symptoms, diagnosis and prognosis for this rare yet debilitating condition.
Acute Hepatic Porphyria Learning Zone
Acute Hepatic Porphyria (AHP), a subset of porphyria, refers to a family of rare, genetic diseases characterised by potentially life-threatening attacks and, for some patients, chronic manifestations that negatively impact daily functioning and quality of life (QOL).1 The most common manifestation of attacks is severe, diffuse abdominal pain, although patients can also experience other pain, mood, and gastrointestinal (GI) symptoms.
Related news and insights
Deciphera Pharmaceuticals, Inc. announced that the Journal of Clinical Oncology has published results from its Phase 1 study of Qinlock, the Company’s switch-control tyrosine kinase inhibitor, in patients with second-line through fourth-line plus gastrointestinal stromal tumor (GIST).
Deciphera Pharmaceuticals announced that Health Canada has authorized Qinlock (ripretinib), a switch-control tyrosine kinase inhibitor, for sale in Canada for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with imatinib, sunitinib, and regorafenib.
You may be interested in...
The Union-North America Region (NAR) is the regional arm of the International Union against Tuberculosis and Lung Disease (The Union), a global public health organization with the vision to provide health solutions to the poor.
28th Conference On Retrovirus And Opportunistic Infections 2021
CROI is the preeminent meeting in the world and attracts more than 4,000 research leaders from nearly 90 countries and nearly half of CROI attendees come from outside the United States. In recent years, more than 1000 abstracts have been selected for presentation at CROI.